| . | OL phasea . | DB phase . | Total n = 208 . | ||||
|---|---|---|---|---|---|---|---|
| Category, n (%) . | 80 U n = 7 . | Placebo n = 25 . | 20 U n = 50 . | 40 U n = 50 . | 60 U n = 49 . | 80 U n = 52 . | . |
| Subjects with ≥1 TEAE | 1 (14.3) | 2 (8.0) | 12 (24.0) | 14 (28.0) | 13 (26.5) | 12 (23.1) | 52 (25.0) |
| Headache | 0 | 0 | 2 | 3 | 7 | 1 | 13 (6.3) |
| Seasonal allergy | 0 | 1 | 0 | 3 | 2 | 1 | 6 (2.9) |
| Influenza | 0 | 1 | 2 | 2 | 1 | 0 | 5 (2.4) |
| URTI | 0 | 0 | 3 | 0 | 0 | 1 | 4 (1.9) |
| Bronchitis | 0 | 0 | 1 | 2 | 0 | 0 | 3 (1.4) |
| Any treatment-related AE | 1 (14.3) | 0 | 1 (2.0) | 2 (4.0) | 3 (6.1) | 3 (5.8) | 10 (4.8) |
| Headache | 0 | 0 | 0 | 2 | 3 | 1 | 6 (2.9) |
| Eyelid ptosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.5) |
| Contusion | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Brow ptosis | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.5) |
| Madarosis | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Serious AE | 0 | 0 | 0 | 0 | 1 (2.0) | 0 | 1 (0.5) |
| Cervical cancer | 0 | 0 | 0 | 0 | 1 | 0 | 1 (0.5) |
| AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| . | OL phasea . | DB phase . | Total n = 208 . | ||||
|---|---|---|---|---|---|---|---|
| Category, n (%) . | 80 U n = 7 . | Placebo n = 25 . | 20 U n = 50 . | 40 U n = 50 . | 60 U n = 49 . | 80 U n = 52 . | . |
| Subjects with ≥1 TEAE | 1 (14.3) | 2 (8.0) | 12 (24.0) | 14 (28.0) | 13 (26.5) | 12 (23.1) | 52 (25.0) |
| Headache | 0 | 0 | 2 | 3 | 7 | 1 | 13 (6.3) |
| Seasonal allergy | 0 | 1 | 0 | 3 | 2 | 1 | 6 (2.9) |
| Influenza | 0 | 1 | 2 | 2 | 1 | 0 | 5 (2.4) |
| URTI | 0 | 0 | 3 | 0 | 0 | 1 | 4 (1.9) |
| Bronchitis | 0 | 0 | 1 | 2 | 0 | 0 | 3 (1.4) |
| Any treatment-related AE | 1 (14.3) | 0 | 1 (2.0) | 2 (4.0) | 3 (6.1) | 3 (5.8) | 10 (4.8) |
| Headache | 0 | 0 | 0 | 2 | 3 | 1 | 6 (2.9) |
| Eyelid ptosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.5) |
| Contusion | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Brow ptosis | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.5) |
| Madarosis | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Serious AE | 0 | 0 | 0 | 0 | 1 (2.0) | 0 | 1 (0.5) |
| Cervical cancer | 0 | 0 | 0 | 0 | 1 | 0 | 1 (0.5) |
| AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AE, adverse event; DB, double-blind; OL, open-label; TEAE, treatment-emergent adverse event; URTI, upper respiratory tract infection.
aAll subjects (N = 233) who received at least 1 injection (OL phase, n = 7; DB phase, n = 226).
| . | OL phasea . | DB phase . | Total n = 208 . | ||||
|---|---|---|---|---|---|---|---|
| Category, n (%) . | 80 U n = 7 . | Placebo n = 25 . | 20 U n = 50 . | 40 U n = 50 . | 60 U n = 49 . | 80 U n = 52 . | . |
| Subjects with ≥1 TEAE | 1 (14.3) | 2 (8.0) | 12 (24.0) | 14 (28.0) | 13 (26.5) | 12 (23.1) | 52 (25.0) |
| Headache | 0 | 0 | 2 | 3 | 7 | 1 | 13 (6.3) |
| Seasonal allergy | 0 | 1 | 0 | 3 | 2 | 1 | 6 (2.9) |
| Influenza | 0 | 1 | 2 | 2 | 1 | 0 | 5 (2.4) |
| URTI | 0 | 0 | 3 | 0 | 0 | 1 | 4 (1.9) |
| Bronchitis | 0 | 0 | 1 | 2 | 0 | 0 | 3 (1.4) |
| Any treatment-related AE | 1 (14.3) | 0 | 1 (2.0) | 2 (4.0) | 3 (6.1) | 3 (5.8) | 10 (4.8) |
| Headache | 0 | 0 | 0 | 2 | 3 | 1 | 6 (2.9) |
| Eyelid ptosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.5) |
| Contusion | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Brow ptosis | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.5) |
| Madarosis | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Serious AE | 0 | 0 | 0 | 0 | 1 (2.0) | 0 | 1 (0.5) |
| Cervical cancer | 0 | 0 | 0 | 0 | 1 | 0 | 1 (0.5) |
| AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| . | OL phasea . | DB phase . | Total n = 208 . | ||||
|---|---|---|---|---|---|---|---|
| Category, n (%) . | 80 U n = 7 . | Placebo n = 25 . | 20 U n = 50 . | 40 U n = 50 . | 60 U n = 49 . | 80 U n = 52 . | . |
| Subjects with ≥1 TEAE | 1 (14.3) | 2 (8.0) | 12 (24.0) | 14 (28.0) | 13 (26.5) | 12 (23.1) | 52 (25.0) |
| Headache | 0 | 0 | 2 | 3 | 7 | 1 | 13 (6.3) |
| Seasonal allergy | 0 | 1 | 0 | 3 | 2 | 1 | 6 (2.9) |
| Influenza | 0 | 1 | 2 | 2 | 1 | 0 | 5 (2.4) |
| URTI | 0 | 0 | 3 | 0 | 0 | 1 | 4 (1.9) |
| Bronchitis | 0 | 0 | 1 | 2 | 0 | 0 | 3 (1.4) |
| Any treatment-related AE | 1 (14.3) | 0 | 1 (2.0) | 2 (4.0) | 3 (6.1) | 3 (5.8) | 10 (4.8) |
| Headache | 0 | 0 | 0 | 2 | 3 | 1 | 6 (2.9) |
| Eyelid ptosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.5) |
| Contusion | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Brow ptosis | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.5) |
| Madarosis | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.5) |
| Serious AE | 0 | 0 | 0 | 0 | 1 (2.0) | 0 | 1 (0.5) |
| Cervical cancer | 0 | 0 | 0 | 0 | 1 | 0 | 1 (0.5) |
| AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AE, adverse event; DB, double-blind; OL, open-label; TEAE, treatment-emergent adverse event; URTI, upper respiratory tract infection.
aAll subjects (N = 233) who received at least 1 injection (OL phase, n = 7; DB phase, n = 226).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
